A new study has reported that the additive neuroprotection of a combination of two omega-3 fatty acid-derived signalling molecules is more effective in protecting brain cells and increasing recovery from stroke in an experimental model than a single drug.
Senior author of the study, Dr Nicolas Bazan, says: “We discovered a compelling effective combinatorial therapy in experimental stroke.
“Despite increasing knowledge of the physiologic, mechanistic, and imaging characterisations of stroke, no effective neuroprotective therapy has been found to date. Most current work uses different approaches with a ‘single’ bullet therapy. Since stroke is so complex and due to multiple damaging factors, we extensively explored a multidisciplinary approach, a combinatorial therapy, that yielded promising beneficial results.”
The researchers examined the bioactivity of Neuroprotectin D1 (NPD1 – discovered by the Bazan lab in 2003) combined with Resolvin D1 (RvD1) in experimental stroke.
These two naturally occurring neuroprotective molecules in the brain derived from docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) called docosanoids have been shown to limit excessive inflammatory responses, regulate metabolism and immune cell functions, decrease the production of proinflammatory factors, and promote tissue repair and stability.
This research was conducted by a team at LSU Health New Orleans’ Neuroscience Center of Excellence.
Under the guidance of Dr. Bazan, LSU Health New Orleans graduate student and first author Madigan Reid designed and performed gene expression studies that showed the combination treatment elicited the selective expression of genes contributing to cell survival.
The research team discovered that the combination therapy boosted the uptake of an anti-inflammatory stroke-associated gene by 123-fold, a gene that regulates new brain cell and blood vessel growth by 100-fold, and two markers of the stability of the brain cells that regulate brain development, maintenance of neuronal networks and injury repair by ten- and fivefold, respectively.
Ludmila Belayev, Professor of Neurosurgery, Neurology and Neuroscience at LSU Health New Orleans Neuroscience Center, says: “We show that NPD1 + RvD1 remarkably improves neurological function and reduces lesion volume in acute ischemic stroke when administered promptly in moderate doses.
“We also demonstrated a broad therapeutic window of neuroprotection with moderate doses of NPD1 + RvD1, such that treatment initiated even 6 hours after stroke onset is highly effective. This combinatorial therapy may promise future therapeutic development against ischaemic stroke.”
Dr Bazan, concludes: ““The biological activity of NPD1 plus RvD1 is due to specific activation and modulation of signalling pathways associated with the immune system, inflammation, cell survival, and cell-cell interactions.
“These findings provide a major conceptual advance of broad therapeutic relevance for cell survival, brain function and, particularly, stroke and neurodegenerative diseases.”
